NASDAQ:AMRSAmyris Stock Price, Forecast & News

Amyris' stock was trading at $2.96 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AMRS stock has increased by 19.3% and is now trading at $3.53. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amyris.

Amyris is scheduled to release its next quarterly earnings announcement on Monday, October 5th 2020. View our earnings forecast for Amyris.

Amyris Inc (NASDAQ:AMRS) announced its quarterly earnings data on Friday, May, 8th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $0.37. The biotechnology company earned $29.13 million during the quarter, compared to analyst estimates of $34.51 million. View Amyris' earnings history.

Amyris's stock reverse split on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.

Amyris issued an update on its FY 2020 Pre-Market earnings guidance on Friday, May, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $220.32-220.32 million, compared to the consensus revenue estimate of $246.44 million.

2 brokerages have issued 1 year price targets for Amyris' shares. Their forecasts range from $8.00 to $11.00. On average, they anticipate Amyris' share price to reach $9.50 in the next twelve months. This suggests a possible upside of 169.1% from the stock's current price. View analysts' price targets for Amyris.

News coverage about AMRS stock has been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Amyris earned a news sentiment score of -1.6 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutAmyris.

Some companies that are related to Amyris include Phillips 66 (PSX), Valero Energy (VLO), Marathon Petroleum (MPC), HollyFrontier (HFC), CVR Energy (CVI), World Fuel Services (INT), Delek US (DK), PBF Energy (PBF), Renewable Energy Group (REGI), Clean Energy Fuels (CLNE), REX American Resources (REX), Green Plains (GPRE), Adams Resources & Energy (AE) and Gevo (GEVO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Gevo (GEVO), Keryx Biopharmaceuticals (KERX), Advanced Micro Devices (AMD), Canopy Growth (CGC), Intel (INTC), Inovio Pharmaceuticals (INO), Novavax (NVAX), AT&T (T), Bank of America (BAC) and Corbus Pharmaceuticals (CRBP).

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

Amyris' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vivo Capital LLC (3.96%), BlackRock Inc. (2.83%), Pinnacle Associates Ltd. (1.15%), State Street Corp (0.68%), Geode Capital Management LLC (0.46%) and Nuveen Asset Management LLC (0.18%). Company insiders that own Amyris stock include Eduardo Alvarez, Frank Kung, John Melo, Kathleen Valiasek, L John Doerr and Patrick Y Yang. View institutional ownership trends for Amyris.

AMRS stock was sold by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, BlackRock Inc., Jane Street Group LLC, JPMorgan Chase & Co., Levin Capital Strategies L.P., Morgan Stanley, UBS Group AG, and Virtus ETF Advisers LLC. Company insiders that have sold Amyris company stock in the last year include John Melo, and Patrick Y Yang. View insider buying and selling activity for Amyris.

AMRS stock was acquired by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Pinnacle Associates Ltd., KPCB XII Associates LLC, State Street Corp, Alliancebernstein L.P., Nuveen Asset Management LLC, Geode Capital Management LLC, and Paloma Partners Management Co. Company insiders that have bought Amyris stock in the last two years include Eduardo Alvarez, Frank Kung, Kathleen Valiasek, L John Doerr, and Patrick Y Yang. View insider buying and selling activity for Amyris.

Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AMRS stock can currently be purchased for approximately $3.53.

Amyris has a market capitalization of $578.53 million and generates $152.56 million in revenue each year. The biotechnology company earns $-242,770,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis. Amyris employs 414 workers across the globe.

The official website for Amyris is amyris.com.

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected]